TreatmentTrends

August 2013

TreatmentTrends®: Gram Negative Infections (US) 2013

Introduction:

Serious Gram-negative (GN) pathogens are clinically-important patho-gens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a high incidence of drug resistance to even the most powerful of antibiotics (e.g. third-generation cephalosporins, fluoroquinolones, and carbapenems). Howev-er, there have only been three new agents approved in the last ten years. As a result, there is a high need for new therapies for multi-drug-resistant (MDR) GN pathogens.
This report provides insight into the management of patients with GN in-fections in the hospital setting and analyzes the hospital antibiotic pre-scribing practices for the treatment of key infections due to emerging and clinically-important Gram-negative pathogens. The study provides longitu-dinal information on market dynamics, including insight into practice pat-terns, attitudes and perceptions, unmet needs, and projected use of anti-biotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and thera-pies in development

Questions Answered in This Report:

  *   How are physicians treating serious infections due to emerging and clinically-important pathogens?
Which pathogens are of concern to physicians, and which pose new treatment challenges and drug de-velopment opportunities?

  *   How do physicians make treatment choices for GN infections, includ-ing empiric treatment for suspected GN infections and discharge ther-apies?


  *   How are severe skin infections, blood stream infections, nosocomial pneumonia, intra-abdominal infections, and bone and joint infections treated?


  *   What are physicians’ therapy preferences and what factors and drug attributes influence current and future prescribing patterns?
How re-ceptive are physicians to novel and emerging therapies?

Scope:

Sample Methodology:

100 infectious diseases specialists completed a 45-minute online quanti-tative survey with several open-ended questions for qualitative feedback.

To qualify, respondents met the following criteria:

Be board-certified in infectious diseases

Treated a minimum of 10 patients with MRSA within the last month

Have been in practice a minimum of 2 years and a maximum of 30 years

At east 50 percent of time practicing in the hospital setting

Key Drugs Covered:

Merrem (meropenem), Primaxin(imipenem/cilastatin), Doribax (doripenem), Invanz (ertapenem), Zosyn (piperacillin/tazobactam), Tygacil (tigecycline), Levaquin(levofloxacin), Avelox (moxifloxacin), other key generic competition, and agents in late-stage development including CXA-201, ceftobiprole, CAZ-AVI, and TP-434

Deliverables:

Final report in PowerPoint format

Trending will be provided for clients purchasing relevant previous reports

Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

Physician and Payer Forum®: Gram-Negative Infections (US)

Physician and Payer Forum®: Gram-Negative Infections (EU)

DecisionBase®: Hospital-Acquired Pneumonia

TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)

PatientBase®: Hospital-Treated Infections in G7

Pharmacor®: Hospital-Treated Infections

Pharmacor®: Methicillin-Resistant Staphylococcus aureus

Hospital Formulary Insights®: Anti-Infectives (US)

Hospital Formulary Insights®: Antibiotics (EU)

TreatmentTrends®: Clostridium difficile Infections (EU)

TreatmentTrends®: Clostridium difficile Infections (US)

Search Published Reports


Mentioned in this report:

  • Achaogen
  • AstraZeneca
  • Cubist
  • Forest Laboratories
  • Johnson & Johnson / Janssen
  • Merck
  • Pfizer
  • Tetraphase Pharmaceuticals
Decision Resources Group brands include: